ONC - BeiGene Oncology Revenue Growth Rate YoY (Last Twelve Months)

BeiGene Ltd (ONC) operates in a defensive sector where demand for therapy remains stable across any economic cycle. The rolling 12-month sales growth rate year-over-year demonstrates revenue dynamics, while 33.00 expresses the current value of this metric. The company aims to become a global disruptor, leveraging its Chinese base to capture Western markets. A breakthrough R&D pipeline of new inhibitors ensures the competitiveness of its innovations.
BeiGene - analytical breakdowns and key metrics (ONC)

BeiGene Ltd strategic alliances in oncology and molecule licensing translate directly into revenue scaling, as reflected in the LTM annual sales growth. This indicator calculates the percentage shift in revenue over the trailing twelve months relative to the previous year, allowing investors to assess the real pace of business expansion and its resilience to market shocks without quarterly distortions.